dc.creator | Carrasco, Cristian | |
dc.creator | Tittarelli, Andrés | |
dc.creator | Paillaleve, Natalia | |
dc.creator | Pozo, Maeva del | |
dc.creator | Rojas Sepúlveda, Daniel Alberto | |
dc.creator | Barría Catricura, Omar André | |
dc.creator | Fluxá Rojas, Paula Andrea | |
dc.creator | Hott, Melissa | |
dc.creator | Martin, Carolina | |
dc.creator | Quezada Monrás, Claudia Andrea | |
dc.creator | Salazar Onfray, Flavio Andres | |
dc.date.accessioned | 2021-11-29T22:26:46Z | |
dc.date.accessioned | 2022-01-27T19:28:56Z | |
dc.date.available | 2021-11-29T22:26:46Z | |
dc.date.available | 2022-01-27T19:28:56Z | |
dc.date.created | 2021-11-29T22:26:46Z | |
dc.date.issued | 2021 | |
dc.identifier | Diagnostics 2021, 11, 153 | |
dc.identifier | 10.3390/diagnostics11020153 | |
dc.identifier | https://repositorio.uchile.cl/handle/2250/182946 | |
dc.identifier.uri | http://repositorioslatinoamericanos.uchile.cl/handle/2250/3310660 | |
dc.description.abstract | Gallbladder cancer (GBC) is an aggressive and highly lethal disease with relatively low global incidence, but one that constitutes a major health problem in Asian and Latin American countries, particularly in Chile. The identification of new tumor-associated markers with potential prognosis value is required for GBC clinical practice. Using immunohistochemistry/tumor tissue microarray, we evaluated the expression of 17 gastrointestinal tumor-associated protein markers (CK7, CK17, CK19, CK20, CKLMW, CKHMW, MUC1, MUC2, MUC5AC, MUC6, CA125, CD10, CEA, vimentin, villin, claudin-4, and CDX2) in primary gallbladder adenocarcinomas from 180 Chilean patients and analyzed potential associations with their pathological and clinical characteristics. Younger female patients with well-to moderately differentiated tumors had a better prognosis than that of older female or male patients with tumors with a similar tumor differentiation grade. Among all analyzed markers, MUC6 expression was associated with better prognosis in patients with well-to moderately differentiated tumors, whereas CK17 or CD10 was associated with worse prognosis in patients with poorly differentiated tumors. In addition, the MUC6(+)CK17(-) expression pattern was strongly associated with better prognosis in patients with well- to moderately differentiated tumors, whereas patients with poorly differentiated tumors and with the CK17(+)CD10(+) expression pattern showed worse prognosis. Our results suggest that tumor MUC6, CK17, and CD10 can be considered as potential prognosis markers for GBC. | |
dc.language | en | |
dc.publisher | MDPI | |
dc.rights | http://creativecommons.org/licenses/by-nc-nd/3.0/us/ | |
dc.rights | Attribution-NonCommercial-NoDerivs 3.0 United States | |
dc.source | Diagnostics | |
dc.subject | Gallbladder cancer | |
dc.subject | Prognosis | |
dc.subject | Biomarkers | |
dc.subject | Mucin 6 | |
dc.subject | Cytokeratin 17 | |
dc.subject | CD10 | |
dc.subject | Immunohistochemistry | |
dc.subject | Tissue microarray | |
dc.title | The evaluation of 17 gastrointestinal tumor markers reveals prognosis value for MUC6, CK17, and CD10 in gallbladder-cancer patients | |
dc.type | Artículos de revistas | |